6Kendzor DE,Businelle MS,Mazas CA,et al.Pathways between socioeconomic status and modifiable risk factors among African American smokers[J].J Behav Med,2009,32 (6):545-557.
7Wiesmann F,Petersen SE,Leeson PM,et al.Global impairment of brachial,carotid and aortic vascular function in young smokers:direct quantification by high-resolution magnetic resonance imaging[J].JACC,2004,44(10):2056-2064.
8Aubin HJ,Bobak A,Britton JR,et al.Varenicline versus transdermal nicotine patch for smoking cessation:results from a randomised open-label trial[J].Thorax,2008,63(8):717-724.
9Celermajer DS,Sorensen KE,Gooch VM,et al.Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis[J].Lancet,1992,340(8828):1111-1115.
10Jarvis MJ.Why people smoke[J].BMJ,2004,328 (7434):277-279.
3Li Q, Hsia J,Yang G.Prevalence of smoking in China in 2010 [J].N Engl J Med,2011 ,364(25):2469-2470.
4中华人民共和国卫生部.中国吸烟危害健康报告[M].北京:人民卫生出版社,2012:1-20.
5A Clinical Practice Guideline Treating Tobacco Use and Dependence2008 Update Panel, Liaisons, and Staff.A Clinical Practice Guide-line for Treating Tobacco Use and Dependence: 2008 Update A U.S.Public Health Service Repor[ J]t.Am J Prev Med,2008 ,35(2):158-176.
7Coe JW, Brooks PR,Wirtz MC,et al.3 ,5-Bicyclic aryl piperidines: anovel class of alpha4beta2 neuronal nicotinic receptor partial ago-nists for smoking cessation [ J].Bioorg Med Chem Lett, 2005 , 15(22):4889-4897.
8Obach RS,Reed-Hagen AE,Krueger SS,et al.Metabolism and dis-position of varenicline, a selective alpha4beta2 acetylcholine recep-tor partial agonist, in vivo and in vitro [ J].Drug Metab Dispos,2006,34(1):121-130.
9Faessel HM,Smith BJ,Gibbs MA,et al.Single-dose pharmacokinet-ics of varenicline,a selective nicotinic receptor partial agonist,inhealthy smokers and nonsmokers [ J].J Clin Pharmacol,2006,46(9):991-998.
10Burstein AH,Fullerton T,Clark DJ'et al.Pharmacokinetics,safety,and tolerability after single and multiple oral doses of varenicline inelderly smokers [ J].J Clin Pharmacol, 2006 ,46( 11): 1234-1240.
